Elite Pharmaceuticals, Inc. (ELTP) Net income 2017–2026
Elite Pharmaceuticals, Inc. (ELTP) annual net income history from SEC filings — each fiscal year as reported, with year-over-year change.
$44.9MFY2026 · since FY2017: $3.8M → $44.9M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | $44.9M | +1140.0% |
| FY2025 | -$4.3M | -121.5% |
| FY2024 | $20.1M | +464.6% |
| FY2023 | $3.6M | -60.0% |
| FY2022 | $8.9M | +74.9% |
| FY2021 | $5.1M | +327.1% |
| FY2020 | -$2.2M | +75.9% |
| FY2019 | -$9.3M | -152.6% |
| FY2018 | -$3.7M | -196.4% |
| FY2017 | $3.8M | — |
Source: SEC XBRL filings · For reference only · Not investment advice
More ELTP financial trends
ELTP RevenueELTP Net marginELTP Gross profitELTP Gross marginELTP Operating incomeELTP Operating marginELTP Operating cash flowELTP Free cash flowELTP Capital expendituresELTP Return on equityELTP Stock buybacksELTP Dividends paidELTP Total assetsELTP Total liabilitiesELTP Shareholders’ equityELTP overview →